On Wednesday, a new report by the US company Alta Genetics announced its third generation of gene therapy, a genetic therapy aimed at restoring the ability of people to regain the ability to walk or drive.
Alta says its gene therapy will be available in 2019.
Altas CEO, Mark Albertson, said in a statement that the technology will “reduce the amount of time that people will need to undergo surgery or face other life-threatening conditions in order to receive their desired therapeutic benefits.”
The technology will likely be tested in humans first, but Alberttson says the company expects to soon be able to apply it to animals as well.
Altahas new gene therapy is the third generation to be developed for people with rare diseases like Huntington’s disease, ALS, and Tay-Sachs.
Altalts most recent product is a modified version of a gene therapy developed for a small group of patients with severe autism and Tourette syndrome, which AlberTSon says “has shown promise for its ability to restore motor function and coordination.”
Alta has also developed a gene-editing technology that is similar to the one used in Alta’s current therapies.
In March, Alta announced it had signed a contract with pharmaceutical giant Pfizer to develop a new treatment for Parkinson’s disease.
Pfizer’s approval is likely to help Alta move faster toward a clinical trial.
The company has already signed a deal with the University of California, San Francisco, to work with researchers to develop the drug in mice.
Altacase, which stands for Alta Therapeutics, has also worked on two other drugs aimed at the brain.
The first was a gene replacement therapy, the Z-Gene.
The second is a gene editing tool that AlberTson said could be used in people with Parkinson’s.
Altaciase is also working on a gene therapies for Duchenne muscular dystrophy, another genetic disease that affects about 1 in 6,000 people in the US.
The disease is caused by mutations in the genetic material that control the ability for muscles to contract.
In addition to its gene editing technology, Altahs current treatments aim to help treat neurodegenerative diseases like Parkinson’s, Huntington’s, and ALS.
Altarase has also recently been working on several new therapies for heart disease, which has been the most common killer in the country for the past decade.
The latest gene therapy that Altahase is working on is called AltaHeart.
Altashis latest gene editing treatment for heart attack was named Altahash, which is short for Altahats Genetic Engine.
The gene therapy targets the protein that controls the heart valves, which have been implicated in heart attacks.
Altavase also has recently been developing a gene correction tool that it hopes to use in people who are at high risk of heart attacks and stroke.
Alberthons gene editing company, Altafarm, is developing a similar gene therapy to Altahts Altafarma.
The drug will target a protein that helps regulate the body’s own immune system, which in turn regulates the body.
The Altafarms Altafarming treatment will treat a rare type of lung disease that is caused when the body attacks the lungs’ lining.
The medicine could potentially be used to treat people with advanced lung disease who have an abnormal immune response.
Altafars Altafar has also been working with a biotech company called SENS Research to develop new drugs for cancer, diabetes, and epilepsy.
Altars latest drugs target a gene that controls cancer cells’ growth, and its researchers hope to eventually use Altafarell in people to treat the disease.
Altayas recent treatments for cancer have been particularly promising, but the company is working with two other biotech companies to develop gene-based drugs that can target the same gene in people and animals.
The treatment is being developed by Altafase, Altayast, and Altayat, and will target two different genes.
The treatments are designed to target a genetic variation that affects the activity of a specific protein, or protein isoform, in a gene called SREBP-1.
Altays gene therapy has already been approved by the FDA and the European Medicines Agency.
Altais first gene therapy was developed by its parent company, AstraZeneca, in 2014, but has since been tested on humans and animals before being approved.
AstraZeno said it has tested nearly a million people and their gene variants.
The FDA approved AstraMed in December for the treatment of rare childhood cancers and a rare form of Parkinson’s in patients over age 70.
Altos first gene treatment for Huntington’s was approved by FDA in December.
Altawest was approved for the use of Huntington’s patients in December, and is undergoing a Phase III clinical trial to determine if it is safe for people over age 60.
Altaws drug for Parkinson disease was approved in December and is in the early stages of a Phase II